ORMP
Oramed Pharmaceuticals Inc. NASDAQ Listed May 1, 2007$4.01
Pre-mkt
$3.93
-2.00%
Mkt Cap $170.1M
52w Low $2.06
73.0% of range
52w High $4.73
50d MA $3.97
200d MA $3.18
P/E (TTM)
1.6x
EV/EBITDA
1.5x
P/B
1.9x
Debt/Equity
0.0x
ROE
32.1%
P/FCF
-18.6x
RSI (14)
54.80
ATR (14)
$0.18
Beta
1.25
50d MA
$3.97
200d MA
$3.18
Avg Volume
209.5K
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
1185 Avenue of the Americas · New York City, NY 10036 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.08 | -0.06 | +25.0% | 3.32 | -0.9% | -0.3% | -0.9% | +3.7% | -0.3% | +0.9% | — |
| Nov 13, 2025 | AMC | -0.04 | 1.13 | +2925.0% | 2.40 | -2.1% | -2.9% | +0.4% | +6.4% | +0.4% | -3.2% | — |
| Aug 14, 2025 | AMC | -0.04 | -0.05 | -25.0% | 2.12 | -5.7% | -1.9% | +0.0% | -1.0% | +0.5% | -0.5% | — |
| May 15, 2025 | AMC | -0.03 | -0.19 | -533.3% | 2.20 | +0.0% | -2.3% | -0.5% | +0.5% | -1.9% | +1.9% | — |
| Mar 27, 2025 | AMC | -0.03 | 0.01 | +133.3% | 2.30 | +0.9% | -3.9% | -3.2% | -0.5% | +3.3% | -1.8% | — |
| Nov 7, 2024 | AMC | -0.00 | -0.48 | -9695.9% | 2.38 | -0.8% | -2.9% | +0.4% | +0.9% | -0.9% | +0.9% | — |
| Aug 14, 2024 | AMC | 0.01 | 0.26 | +2500.0% | 2.24 | +7.1% | +4.9% | -0.4% | +1.3% | +1.3% | +2.9% | — |
| May 9, 2024 | AMC | 0.02 | 0.04 | +100.0% | 2.38 | -0.4% | +0.8% | +0.4% | +2.5% | -3.2% | -2.5% | — |
| Mar 6, 2024 | AMC | -0.12 | -0.08 | +33.3% | 2.87 | -2.4% | -0.3% | +4.2% | -1.3% | -2.7% | -3.1% | — |
| Nov 9, 2023 | AMC | -0.09 | -0.08 | +11.1% | 1.95 | +1.0% | -1.5% | +3.6% | +3.0% | +0.5% | -1.0% | — |
| Aug 10, 2023 | AMC | -0.11 | -0.03 | +72.7% | 3.19 | -0.6% | +2.5% | -4.6% | +0.3% | -7.0% | +8.2% | — |
| May 11, 2023 | AMC | -0.23 | -0.08 | +65.2% | 2.82 | -0.4% | +0.4% | +10.6% | +24.3% | -6.7% | +13.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 17 | Canaccord Genuity | Maintains | Hold → Hold | — | $3.89 | $3.89 | +0.0% | -6.7% | +13.2% | +8.5% | -0.7% | +0.9% |
| Jan 17 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $2.25 | $2.16 | -4.0% | -10.2% | +7.9% | -3.2% | -2.4% | -1.0% |
| Jan 12 | Canaccord Genuity | Downgrade | Buy → Hold | — | $10.79 | $2.37 | -78.0% | -76.5% | -11.4% | -10.2% | +7.9% | -3.2% |
| May 16 | Aegis Capital | Maintains | Buy → Buy | — | $4.57 | $4.62 | +1.1% | +7.0% | +5.1% | -13.4% | +1.6% | +0.2% |
| Feb 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $10.63 | $10.86 | +2.2% | -0.7% | -3.9% | -6.1% | +6.4% | -0.1% |
| Nov 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.31 | $18.52 | +1.1% | +5.0% | -8.0% | -1.0% | -11.9% | +1.0% |
| Nov 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.21 | $21.19 | +4.8% | -9.4% | +5.0% | -8.0% | -1.0% | -11.9% |
| Nov 2 | Aegis Capital | Maintains | Buy → Buy | — | $25.08 | $25.47 | +1.6% | +14.8% | -12.9% | +5.6% | +1.3% | +10.9% |
| Jul 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $13.81 | $13.94 | +0.9% | +5.6% | -2.7% | +5.3% | +3.7% | -2.5% |
| Jun 8 | Aegis Capital | Maintains | Buy → Buy | — | $13.60 | $13.65 | +0.4% | +1.8% | +5.3% | -0.8% | -2.1% | +0.6% |
| Apr 20 | Canaccord Genuity | Maintains | Buy → Buy | — | $8.46 | $8.82 | +4.3% | -1.4% | +10.6% | +1.4% | +4.6% | +4.8% |
| Feb 9 | National Securities Corporation | Maintains | Buy → Buy | — | $10.43 | $10.65 | +2.1% | +0.1% | -3.7% | +1.5% | +7.8% | +1.0% |
| Jan 27 | Aegis Capital | Maintains | Buy → Buy | — | $6.84 | $6.46 | -5.6% | +1.5% | +0.9% | +3.7% | +18.9% | +9.3% |
| Jul 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.33 | $3.42 | +2.7% | +3.3% | +4.4% | +13.1% | +0.5% | -2.5% |
| Jun 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.05 | $4.12 | +1.7% | +1.7% | -5.1% | -4.9% | -1.6% | -1.4% |
| Sep 11 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $2.97 | $3.09 | +4.0% | -2.0% | +3.1% | +1.7% | -1.0% | +4.3% |
| Nov 19 | FBR Capital | Maintains | Outperform → Outperform | — | $7.09 | $7.23 | +2.0% | +3.8% | +12.5% | -3.3% | -4.5% | -0.3% |
| Oct 1 | H.C. Wainwright | Maintains | Buy → Buy | — | $5.47 | $5.72 | +4.6% | +6.4% | +6.7% | +4.3% | -4.6% | +3.1% |
| Dec 4 | Aegis Capital | Maintains | Buy → Buy | — | $8.03 | $8.03 | +0.0% | +0.7% | -2.3% | -1.1% | +0.9% | +0.6% |
No insider trades available.
NT 10-Q
!! High
Oramed Pharmaceuticals Inc. -- Late Quarterly Report -- Distress Signal
May 15
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
ORMP's acquisition completion signals potential revenue growth and market expansion, but investors should monitor integration execution and debt levels to assess whether synergies justify the purchase price.
Mar 31
8-K · 1.01
! Medium
Oramed Pharmaceuticals Inc. -- 8-K 1.01: Equity Issuance
Oramed Pharmaceuticals entered into a warrant agreement with Scilex Holding Co., potentially diluting existing shareholders while raising capital through warrant exercises at undetermined future prices.
Feb 20
8-K · 1.01
! Medium
Scilex Holding Company -- 8-K 1.01: Equity Issuance
Scilex entered a warrant agreement with Oramed Pharmaceuticals, potentially diluting existing shareholders while providing Scilex capital through warrant exercise proceeds.
Feb 20
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Bml Capital Management, Llc | 3,167,231 | $11M | — | Mar 2026 |
| 2 | Gem Investment Advisors, Llc | 1,640,069 | $6M | Reduced | Mar 2026 |
| 3 | Marshall Wace, Llp | 259,611 | $883K | — | Mar 2026 |
| 4 | Rathbones Group Plc | 233,018 | $792K | — | Mar 2026 |
| 5 | Wells Fargo & Company/mn | 157,586 | $536K | New | Mar 2026 |
| 6 | Renaissance Technologies Llc | 147,700 | $502K | — | Mar 2026 |
| 7 | Bank Of America Corp /de/ | 146,152 | $497K | Reduced | Mar 2026 |
| 8 | Susquehanna International Group, Llp | 136,218 | $463K | Added | Mar 2026 |
| 9 | Citadel Advisors Llc | 98,629 | $335K | Reduced | Mar 2026 |
| 10 | Jane Street Group, Llc | 78,259 | $223K | Added | Dec 2025 |
| 11 | Connor, Clark & Lunn Investment Management Ltd. | 43,735 | $125K | Added | Dec 2025 |
| 12 | Prelude Capital Management, Llc | 35,313 | $120K | Added | Mar 2026 |
| 13 | Bailard, Inc. | 32,478 | $110K | New | Mar 2026 |
| 14 | Morgan Stanley | 35,268 | $101K | Added | Dec 2025 |
| 15 | Hrt Financial Lp | 27,498 | $93K | Reduced | Mar 2026 |
| 16 | Point72 Asset Management | 26,052 | $89K | Added | Mar 2026 |
| 17 | Qube Research & Technologies Ltd | 23,504 | $80K | New | Mar 2026 |
| 18 | Catalyst Funds Management Pty Ltd | 23,500 | $80K | New | Mar 2026 |
| 19 | Redwood Family Wealth Llc | 22,065 | $75K | Reduced | Mar 2026 |
| 20 | Pnc Financial Services Group, Inc. | 21,200 | $72K | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 17
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF | 82,596 | $281K | Mar 2026 |
| 2 | Dimensional U.S. Core Equity 2 ETF | 36,536 | $123K | Jan 2026 |
| 3 | Fidelity Nasdaq Composite Index Fund | 24,282 | $83K | Feb 2026 |
| 4 | U.S. CORE EQUITY 2 PORTFOLIO | 23,349 | $79K | Jan 2026 |
| 5 | Avantis U.S. Small Cap Equity ETF | 17,941 | $61K | Feb 2026 |
| 6 | U.S. SMALL CAP PORTFOLIO | 12,774 | $43K | Jan 2026 |
| 7 | U.S. VECTOR EQUITY PORTFOLIO | 10,581 | $36K | Jan 2026 |
| 8 | Dimensional U.S. Small Cap ETF | 10,085 | $34K | Jan 2026 |
| 9 | U.S. Social Core Equity 2 Portfolio | 4,929 | $17K | Jan 2026 |
| 10 | Dimensional US Core Equity 1 ETF | 4,523 | $15K | Jan 2026 |
| 11 | Avantis U.S. Equity ETF | 4,152 | $14K | Feb 2026 |
| 12 | Victory Extended Market Index Fund | 3,442 | $12K | Jan 2026 |
| 13 | Dimensional U.S. Equity Market ETF | 3,431 | $12K | Jan 2026 |
| 14 | U.S. CORE EQUITY 1 PORTFOLIO | 3,131 | $11K | Jan 2026 |
| 15 | LVIP Dimensional U.S. Core Equity 2 Fund | 2,680 | $9K | Mar 2026 |
| 16 | Guggenheim Active Allocation Fund | 212 | $724 | Feb 2026 |
| 17 | Dimensional US Vector Equity ETF | 4 | $13 | Jan 2026 |
Valuation
Market Cap
$170.1M
Enterprise Value
$119.3M
P/E (TTM)
1.55x
Forward P/E
—
PEG Ratio
-0.00x
P/B
1.94x
P/S
—
P/FCF
-18.58x
EV/EBITDA
1.51x
Shares Out
42.4M
Financials (TTM)
Revenue
$0
Net Income
$110.0M
EBITDA
$78.8M
Free Cash Flow
-$9.2M
Op Cash Flow
-$9.1M
EPS Basic
$1.53
EPS Diluted
$2.58
EPS Forward
$-1.26
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$97.6M
Total Liab.
$12.0M
Total Equity
$199.7M
Cash
$51.4M
LT Debt
$540K
Book Value/Sh
$2.07
Debt/Equity
0.00x
Current Ratio
6.98
Quick Ratio
6.98
Returns & Growth
ROE
32.1%
ROA
27.7%
ROIC
-19.1%
Rev Growth YoY
+0.0%
EPS Growth YoY
+425.5%
Price Returns
2W
-16.1%
1M
+2.3%
3M
+16.1%
6M
+39.3%
12M
+69.7%
Technicals
52W High
$4.73
52W Low
$2.06
50d MA
$3.97
200d MA
$3.18
RSI (14)
54.80
ATR (14)
$0.18
Beta
1.25
Avg Volume
210K
Dividends
Div Rate
$0.26
Div Yield
6.6%
Frequency
—
Ex-Div Date
Jan 16, 2026
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 26, 2026 5:56pm
· Source: financialmodelingprep.com